Top Updates Back
Helios Corporation
株式会社ヘリオス
HEALIOS K.K. Alias
2011-02-24
4593
TYO
Japan
iPSC-based regenerative medicines
somatic stem cell regenerative medicines
Research, development, and manufacturing of cell medicines and regenerative medical products
Universal donor cells
Cancer immunotherapy (NK cells)
Age-related macular degeneration
Liver diseases
Cerebral infarction
Acute respiratory distress syndrome (ARDS)
12th Floor, Hibiya Mitsui Tower, 1-1-2 Yurakucho, Chiyoda-ku, Tokyo, Work Styling
Toshinobu Kagi
2,572,000,000 　(25 100 million)
66 people
66 people
Company name
Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Saisei Capital Ltd.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group Subsidiary
Saisei Ventures LLC
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group Subsidiary
株式会社プロセルキュア
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group Subsidiary
協和発酵キリン株式会社
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
キリンビール株式会社
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
第一三共株式会社
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
藤沢薬品工業株式会社(現アステラス製薬株式会社)
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
フィデリティ投信株式会社
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
ノバルティスファーマ株式会社
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
アストラゼネカ
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
住友ファーマ株式会社
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
株式会社サイレジェン
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
Healios NA, Inc.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group Subsidiary
Nezu Asia Capital Management
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
Saisei Bioventures, L.P.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group Subsidiary
イオンファイナンシャルサービス株式会社
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
ゴールドマン・サックス証券
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
モルガン銀行(現JP Morgan)
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
三井住友信託銀行株式会社証券代行部
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Customer

24 entries
DateDescription
2011-02 Established the company in Higashi-ku, Fukuoka City, Fukuoka Prefecture: Nihon Retina Research Institute (now Helios Corporation).
2011-02 Initiated consideration of a commercialization strategy for iPSC-derived retinal pigment epithelial cell transplantation for age-related macular degeneration.
2012-12 Opened a Tokyo office in Chiyoda-ku, Tokyo.
2013-09 Changed the company name to Helios Corporation. Moved the Tokyo office and headquarters to Chuo-ku, Tokyo.
2013-09 Changed the company name to Helios Co., Ltd.
2013-10 Established a laboratory (now Kobe Research Institute) in Chuo-ku, Kobe.
2013-10 Relocated the Tokyo office and headquarters to Chuo-ku, Tokyo.
2013-12 Acquired the ophthalmic surgical adjunct business from Akumen Corporation.
2013-12 Established a laboratory (now Kobe Research Institute) in Chuo-ku, Kobe.
2014-02 Established a joint venture, Silegen Corporation, with Dai Nippon Sumitomo Pharma (now Sumitomo Pharma).
2014-09 Moved headquarters to Minato-ku, Tokyo.
2015-06 Listed on the Tokyo Stock Exchange Mothers.
2016-01 Signed a license agreement with Athersys, Inc. (USA) for regenerative medical products using MultiStem® stem cells in Japan.
2017-04 Transferred the business related to the ophthalmic surgical adjunct containing BBG250 to De Western Therapeutics Research Institute.
2018-02 Established a subsidiary, Healios NA Inc., in the United States (now a consolidated subsidiary).
2020-01 Commenced application of International Financial Reporting Standards (IFRS).
2020-10 Relocated headquarters to Chiyoda-ku, Tokyo.
2021-01 Established a subsidiary fund in regenerative medicine (currently a consolidated subsidiary), including Saisei Ventures LLC of the United States.
2022-04 Transitioned from the Tokyo Stock Exchange Mothers to the Growth Market due to a review of market classifications by the Tokyo Stock Exchange.
2023-07 Established subsidiary ProCell Cure Co., Ltd. (currently a consolidated subsidiary).
2023-07 Established subsidiary ProCell Cure Co., Ltd. (currently a consolidated subsidiary).
2024-04 Acquired the entire assets of Athersys, Inc. of the United States.
2024-06 Signed a basic business partnership agreement and a corporate bond repurchase agreement with Alphresa Co., Ltd.
2025-01 Established subsidiary Akatsuki Therapeutics Co., Ltd. (currently a consolidated subsidiary).
+ Loaded when opened
3290001055549
Trade name株式会社ヘリオス
Trade name (kana)ヘリオス
Name in English
Corporation type301
Address〒100-0006 東京都千代田区有楽町１丁目１番２号
Postal code1000006
Prefecture code13
City code101
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date2015-10-05
Update date2023-03-07
Change date2023-03-01
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record1
Excluded from search0
Processing type12
Correction type0
Trade name image ID
Address image ID
Sequence number1714811
Source: National Tax Agency Corporate Number Publication Site, basic three items
3290001055549
Corporate number3290001055549
Trade name株式会社ヘリオス
Trade name (kana)ヘリオス
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address東京都千代田区有楽町１丁目１番２号
Postal code1000006
Prefecture東京都
Prefecture code13
City or district千代田区
City code101
Street address有楽町１丁目１番２号
Organisation type301
Processing type12
Correction type0
Status
Representative代表執行役社長CEO　　鍵本　忠尚
Capital2572000000
Employees58
Employees (male)
Employees (female)
Business summary
Website URL
Year founded
Business categoryL:学術研究、専門・技術サービス業
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date2023-03-07
Key information3290001055549
Source: gBizINFO (Ministry of Economy, Trade and Industry)
✅
2026-09-23 01:48 (Model: gpt-4.1-nano )
↑